Business
Xenon Pharmaceuticals Presents Additional Positive Data from Phase 2b ‘X-TOLE’ Clinical Trial at the Annual Meeting of the American Epilepsy Society (AES 2021)
Topline Data Showed All Primary and Secondary Seizure Reduction Endpoints Statistically Significant Across All Dose Groups, with p-value
About this update from Xenon Pharmaceuticals Inc.
[{"type":"text","content":"Topline Data Showed All Primary and Secondary Seizure Reduction Endpoints Statistically Significant Across All Dose Groups, with p-value of","length":169,"tagName":"div"}]